Palvella Therapeutics Inc. Ordinary Shares PVLA 深 滬
等待開盤 07-19 09:30:00 美东时间
30.22
-1.010
-3.23%
華盛通- 最 高31.50
- 今 開31.10
- 成交量 8.46万股
- 最 低 29.50
- 昨 收 31.23
- 總市值 3.34亿
- 52周最高 31.50
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 11.17
- 委 比 90.13%
- 總股本 1105.57万
- 歷史最高 31.50
- 量 比 0.58
- 振 幅 6.40%
- 歷史最低 11.17
- 每 手 1
- 風險率 5.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treating serious, rare genetic skin diseases without FDA-approved therapies, has been added to the Russell 3000® and Russell 2000® indexes effective June 30, 2025. Membership in these indexes reflects the company's market capitalization and is part of the annual reconstitution process. Palvella is developing a pipeline of product candidates, including its lead QTOR...
06-30 11:30
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
Palvella Therapeutics announced the completion of the SELVA Phase 3 trial for QTORIN™ rapamycin in treating microcystic lymphatic malformations (microcystic LMs), enrolling 51 subjects, exceeding the initial target of 40 by 25%. Top-line data is expected in Q1 2026, aiming for an NDA submission in H2 2026. QTORIN™ received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA. Microcystic LMs are a rare, chronic genetic dise...
06-23 11:30
Palvella Therapeutics Receives U.S. Patent Covering 0.1–20% Anhydrous Compositions Of Rapamycin And Other mTOR Inhibitors
New intellectual property builds on Palvella's multi-layered exclusivity strategyPatent term expected through at least 2038- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical
06-18 19:34
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
Palvella Therapeutics received U.S. Patent No. 12,329,748 for QTORIN™ 3.9% rapamycin anhydrous gel, providing broad protection for its composition and use in treating rare skin diseases. This marks the company's sixth U.S. patent, reinforcing its exclusivity strategy through intellectual property, proprietary formulations, and regulatory exclusivities. QTORIN™ has received FDA Breakthrough Therapy, Orphan Drug, and Fast Track Designations, with p...
06-18 11:30
Palvella Therapeutics Receives The Initial Proceeds From A Previously Announced Grant From FDA Office Of Orphan Products Development, The Grant Supports Its Ongoing Phase 3 SELVA trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory expertsUp to $2.6 million in non-dilutive funding anticipated over the grant periodTop-line data
06-09 19:36
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
Palvella Therapeutics has received an FDA Orphan Products Grant to support its Phase 3 SELVA trial for QTORIN™ rapamycin, targeting microcystic lymphatic malformations. The grant, among only seven awarded from 51 applications, provides up to $2.6 million in non-dilutive funding. The SELVA trial, evaluating QTORIN™ in 40 patients, is on track to report top-line data in Q1 2026. There are no FDA-approved treatments for microcystic LMs, a rare genet...
06-09 11:30
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
Palvella Therapeutics appoints Ashley Kline as Chief Commercial Officer to lead the U.S. launch of QTORIN™ rapamycin gel for treating rare genetic skin diseases. Kline, with a proven track record in rare disease commercialization, previously spearheaded the successful launch of Oxervate® at Dompé, achieving over $500 million in annual U.S. sales. Palvella aims to become a leading biopharmaceutical company focused on rare skin diseases, with QTORI...
05-27 12:00
Canaccord Genuity Maintains Buy on Palvella Therapeutics, Lowers Price Target to $52
Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $53 to $52.
05-16 20:49
Palvella Therapeutics Q1 EPS $(0.74) Beats $(1.44) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(1.44) by 48.61 percent.
05-15 19:31
Earnings Scheduled For May 15, 2025
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is expected t...
05-15 16:32
